Congenital Myasthenic Syndromes: Current Diagnostic and Therapeutic Approaches

 

 Buy Article Permissions and Reprints

Abstract

Congenital myasthenic syndromes (CMS) are rare genetically and clinically heterogeneous disorders characterized by an impaired neuromuscular transmission. Exact prevalence data are not available, approximately 2000 to 3000 patients worldwide have been diagnosed on a molecular level; mutations in 14 different genes are known to date leading to causal defects in presynaptic nerve terminal, synaptic cleft, and postsynaptic apparatus. At last, all known mutations are estimated to cause approximately 50% of all clinically diagnosed CMS. However, phenotypes may vary widely and symptoms can be unspecific, therefore CMS are often missed and their prevalence may be underestimated. But, the exact diagnosis is extremely important to start early appropriate therapy to prevent life-threatening events and to improve the clinical course. Most patients are eligible for drug therapy with esterase inhibitors, 3, 4-diaminopyridine, ephedrine, fluoxetine or quinidine, but the effect of these drugs differs depending on the underlying genetic defect. Moreover, very little is known about the best treatment and care in these patients over a longer period of time.

This article provides an overview of specific clinical symptoms, diagnostic work-up, and care including possible pharmacotherapy in case of CMS.

• References

• 1 Della Marina A, Abicht A, Schara U. Kongenitale myasthene Syndrome. Vom Symptom zur Diagnose und Therapie. Nervenheilkunde 2011; 10: 797-804
  PubMedGoogle Scholar
• 2 Engel AG, Sine SM. Current understanding of congenital myasthenic syndromes. Curr Opin Pharmacol 2005; 5 (3) 308-321
  CrossrefPubMedGoogle Scholar
• 3 Engel AG. Current status of the congenital myasthenic syndromes. Neuromuscul Disord 2012; 22 (2) 99-111
  CrossrefPubMedGoogle Scholar
• 4 Hantaï D, Richard P, Koenig J, Eymard B. Congenital myasthenic syndromes. Curr Opin Neurol 2004; 17 (5) 539-551
  CrossrefPubMedGoogle Scholar
• 5 Kinali M, Beeson D, Pitt MC , et al. Congenital myasthenic syndromes in childhood: diagnostic and management challenges. J Neuroimmunol 2008; 201-202: 6-12
  CrossrefPubMedGoogle Scholar
• 6 Maselli RA, Ng JJ, Anderson JA , et al. Mutations in LAMB2 causing a severe form of synaptic congenital myasthenic syndrome. J Med Genet 2009; 46 (3) 203-208
  PubMedGoogle Scholar
• 7 Müller JS, Mihaylova V, Abicht A, Lochmüller H. Congenital myasthenic syndromes: spotlight on genetic defects of neuromuscular transmission. Expert Rev Mol Med 2007; 9 (22) 1-20
  PubMedGoogle Scholar
• 8 Schara U, Abicht A, Müller J, Lochmüller H, Mortier W. Kongenitale myasthene Syndrome – vom Symptom zur Diagnose. Päd 2007; 13: 102-114
  PubMedGoogle Scholar
• 9 Abicht A, Lochmüller H. Congenital Myasthenic Syndromes. In: Pagon RA, Bird TC, Dolan CR, Stephens K, eds. GeneReviews [Internet]. Seattle, WA: University of Washington, Seattle; 1993–2003 May 9 [updated 2006 Sep 26]
  Google Scholar
• 10 Engel AG, Shen XM, Selcen D, Sine SM. What have we learned from the congenital myasthenic syndroms. J Mol Neurosci 2010; 40 (1-2) 143-153
  CrossrefPubMedGoogle Scholar
• 11 Senderek J, Müller JS, Dusl M , et al. Hexosamine biosynthetic pathway mutations cause neuromuscular transmission defect. Am J Hum Genet 2011; 88 (2) 162-172
  CrossrefPubMedGoogle Scholar
• 12 Spillane J, Beeson DJ, Kullmann DM. Myasthenia and related disorders of the neuromuscular junction. J Neurol Neurosurg Psychiatry 2010; 81 (8) 850-857
  CrossrefPubMedGoogle Scholar
• 13 Barisic N, Müller JS, Paucic-Kirincic E , et al. Clinical variability of CMS-EA (congenital myasthenic syndrome with episodic apnea) due to identical CHAT mutations in two infants. Eur J Paediatr Neurol 2005; 9 (1) 7-12
  CrossrefPubMedGoogle Scholar
• 14 Beeson D, Hantaï D, Lochmüller H, Engel AG. 126th International Workshop: congenital myasthenic syndromes, 24-26 September 2004, Naarden, the Netherlands. Neuromuscul Disord 2005; 15 (7) 498-512
  CrossrefPubMedGoogle Scholar
• 15 Chaouch A, Müller JS, Guergueltcheva V , et al. A retrospective clinical study of the treatment of slow-channel congenital myasthenic syndrome. J Neurol 2011; ; Epub ahead of print
  PubMedGoogle Scholar
• 16 Chaouch A, Beeson D, Hantaï D, Lochmüller H. 186th ENMC International Workshop: Congenital myasthenic syndromes 24-26 June 2011, Naarden, The Netherlands. Neuromuscul Disord 2012; 22 (6) 566-576 Epub ahead of print
  CrossrefPubMedGoogle Scholar
• 17 Croxen R, Hatton C, Shelley C , et al. Recessive inheritance and variable penetrance of slow-channel congenital myasthenic syndromes. Neurology 2002; 59 (2) 162-168
  CrossrefPubMedGoogle Scholar
• 18 Guergueltcheva V, Müller JS, Dusl M , et al. Congenital myasthenic syndrome with tubular aggregates caused by GFPT1 mutations. J Neurol 2011; ; Epub ahead of print
  PubMedGoogle Scholar
• 19 Huzé C, Bauché S, Richard P , et al. Identification of an agrin mutation that causes congenital myasthenia and affects synapse function. Am J Hum Genet 2009; 85 (2) 155-167
  CrossrefPubMedGoogle Scholar
• 20 Mihaylova V, Müller JS, Vilchez JJ , et al. Clinical and molecular genetic findings in COLQ-mutant congenital myasthenic syndromes. Brain 2008; 131 (Pt 3) 747-759
  CrossrefPubMedGoogle Scholar
• 21 Mihaylova V, Salih MA, Mukhtar MM , et al. Refinement of the clinical phenotype in musk-related congenital myasthenic syndromes. Neurology 2009; 73 (22) 1926-1928
  CrossrefPubMedGoogle Scholar
• 22 Müller JS, Herczegfalvi A, Vilchez JJ , et al. Phenotypical spectrum of DOK7 mutations in congenital myasthenic syndromes. Brain 2007; 130 (Pt 6) 1497-1506
  CrossrefPubMedGoogle Scholar
• 23 Engel AG. The therapy of congenital myasthenic syndromes. Neurotherapeutics 2007; 4 (2) 252-257
  CrossrefPubMedGoogle Scholar
• 24 Schara U, Lochmüller H. Therapeutic strategies in congenital myasthenic syndromes. Neurotherapeutics 2008; 5 (4) 542-547
  CrossrefPubMedGoogle Scholar
• 25 Schara U, Barisic N, Deschauer M , et al. Ephedrine therapy in eight patients with congenital myasthenic syndrome due to DOK7 mutations. Neuromuscul Disord 2009; 19 (12) 828-832
  CrossrefPubMedGoogle Scholar
• 26 Colomer J, Müller JS, Vernet A , et al. Long-term improvement of slow-channel congenital myasthenic syndrome with fluoxetine. Neuromuscul Disord 2006; 16 (5) 329-333
  CrossrefPubMedGoogle Scholar
• 27 Harper CM, Fukodome T, Engel AG. Treatment of slow-channel congenital myasthenic syndrome with fluoxetine. Neurology 2003; 60 (10) 1710-1713
  CrossrefPubMedGoogle Scholar
• 28 Lashley D, Palace J, Jayawant S, Robb S, Beeson D. Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7. Neurology 2010; 74 (19) 1517-1523
  CrossrefPubMedGoogle Scholar
• 29 Liewluck T, Selcen D, Engel AG. Beneficial effects of albuterol in congenital endplate acetylcholinesterase deficiency and Dok-7 myasthenia. Muscle Nerve 2011; 44 (5) 789-794
  CrossrefPubMedGoogle Scholar
• 30 Palace J, Wiles CM, Newsom-Davis J. 3,4-Diaminopyridine in the treatment of congenital (hereditary) myasthenia. J Neurol Neurosurg Psychiatry 1991; 54 (12) 1069-1072
  CrossrefPubMedGoogle Scholar
• 31 Sadeh M, Shen XM, Engel AG. Beneficial effect of albuterol in congenital myasthenic syndrome with epsilon-subunit mutations. Muscle Nerve 2011; 44 (2) 289-291
  CrossrefPubMedGoogle Scholar
• 32 Schara U, Christen HJ, Durmus H , et al. Long-term follow-up in patients with congenital myasthenic syndrome due to CHAT mutations. Eur J Paediatr Neurol 2010; 14 (4) 326-333
  CrossrefPubMedGoogle Scholar
• 33 Kanzaki A, Motomura M. A pregnant patient with anti-MuSK antibody positive myasthenia gravis and her infant with transient neonatal myasthenia gravis. Rinsho Shinkeigaku 2011; 51 (3) 188-191 abstract in English available
  CrossrefPubMedGoogle Scholar
• 34 Pitt M. Neurophysiological strategies for the diagnosis of disorders of the neuromuscular junction in children. Dev Med Child Neurol 2008; 50 (5) 328-333
  CrossrefPubMedGoogle Scholar
• 35 Munot P, Lashley D, Jungbluth H , et al. Congenital fibre type disproportion associated with mutations in the tropomyosin 3 (TPM3) gene mimicking congenital myasthenia. Neuromuscul Disord 2010; 20 (12) 796-800
  CrossrefPubMedGoogle Scholar
• 36 Robb SA, Sewry CA, Dowling JJ , et al. Impaired neuromuscular transmission and response to acetylcholinesterase inhibitors in centronuclear myopathies. Neuromuscul Disord 2011; 21 (6) 379-386
  CrossrefPubMedGoogle Scholar
• 37 Sanders DB, Massey JM. Clinical features of myasthenia gravis. In: Engel AG, ed. Handbook of Clinical Neurology: Neuromuscular Junction Disorders. Amsterdam, The Netherlands: Elsevier; 2008: 235-236
  Google Scholar
• 38 Schumm F. Cholinergika. In: Fox JM, Jörg J, eds. Neurologische Pharmakotherapie. Stuttgart, New York: Thieme; 2004: 191-220
  Google Scholar
• 39 Sieb JP, Engel AG. Ephedrine: effects on neuromuscular transmission. Brain Res 1993; 623 (1) 167-171
  CrossrefPubMedGoogle Scholar
• 40 Argov Z. Current approach to seronegative myasthenia. J Neurol 2011; 258 (1) 14-18
  CrossrefPubMedGoogle Scholar
• 41 Belaya K, Finlayson S, Slater CR , et al. Mutations in DPAGT1 cause a limb-girdle congenital myasthenic syndrome with tubular aggregates. Am J Hum Genet 2012; 91 (1) 193-201
  CrossrefPubMedGoogle Scholar